Biolab strengthens its Advisory Board with former president of BB, CEO of 3M and former CTO of Itaú
News Lab | February 03, 2025
As part of its strategic restructuring to boost sustainable growth, Biolab Farmacêutica has announced changes to its Advisory Board. CEO Fabio Amorosino takes over as interim chairman of the board, which also includes founding partners Cleiton Castro Marques, Dante Alario and Paulo Castro Marques. In addition, three new independent directors have been brought in to bring perspectives and experiences that will strengthen the future of the organization
Cassio Casseb joins the board to bring his expertise in the financial and business sectors. Having worked for important organizations and strategic leaders, such as the president of Banco do Brasil, Grupo Pão de Açúcar and Coinbra (Dreyfus Group), among others, Cassio will contribute to Biolab with his vision of governance and his commitment to significant results. "I am honored to be part of a company that combines innovation and purpose, and I hope to add my experience to Biolab's success," he said.
João Bezerra Leite, former CTO (Chief Technology Officer) of Itaú Unibanco, has a relevant background in technology and innovation, and joined the Board in November with the aim of boosting Biolab's progress in the digital age. His experience is and will be decisive in driving forward new technologies and the company's operational efficiency. "I am very pleased to be part of projects with purpose and impact like Biolab, in an environment with solid values and surrounded by people who want to transform and from whom I can learn," says João Bezerra.
Paulo Gandolfi, the current CEO of 3M Brazil, brings to the board his vast experience in Research, Development and Innovation (RD&I), aligned with the strategies of various units in the business. His ability to lead multifunctional operations and integrate global strategies will be essential to increasing Biolab's leading role in the health sector. "It's a privilege to contribute to a company recognized for its focus on RD&I and commitment to excellence," says Gandolfi.
With a strengthened Advisory Board, Biolab reaffirms its commitment to innovation, sustainability and the creation of value for the healthcare market, maintaining its position as a benchmark in the sector.
About Biolab:
Biolab is a national pharmaceutical company that invests in research to overcome growing health challenges, renewing its commitment to offering people quality of life.
The four Research, Development and Innovation centers contribute to constant evolution and reinforce the DNA of innovation. Its business lines include Biolab Genéricos, Avert Humana and its animal health arm, Avert, which focuses on supplements and medicines for dogs and cats. There are already more than 500 products, each designed with care and attention so that people and animals live longer and better lives.
In addition to the three production units located in São Paulo, the company has expanded its infrastructure with a modern complex in Pouso Alegre (MG) that complies with legislation in the United States and the European Union, increasing its production capacity fivefold, as well as strengthening its export plans.
Internationally, the business is growing, with innovative products reaching seven countries, including the most regulated in the world. In 2022, it acquired the Canadian laboratory Exzell Pharma. It is also the first Brazilian pharmaceutical company with an RD&I Center abroad, located in Mississauga (Canada).
Together with its 3,800 employees, Biolab is building a history of success and is preparing every day to go further with the determination and certainty that it is following the path of sustainable growth, with responsibility, respect for people and good management practices.
See the full article: Biolab strengthens its Advisory Board with former president of BB, CEO of 3M and former CTO of Itaú | Newslab